Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

被引：0
|
作者：
Llovet, Josep M.
Singal, Amit G.
Villanueva, Augusto
Finn, Richard S.
Kudo, Masatoshi
Galle, Peter R.
Wang, Chunxiao
Widau, Ryan C.
Gugel, Elena Gonzalez
Zhu, Andrew X.
机构：
[1] Icahn Sch Med Mt Sinai, Div Liver Dis, Tisch Canc Inst, New York, NY 10029 USA
[2] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA
[3] Icahn Sch Med Mt Sina, Dept Med, Div Liver Dis, Mt Sinai, NY USA
[4] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA
[5] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[6] Mainz Univ, Dept Internal Med, Med Ctr, Mainz, Germany
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Eli Lilly, Indianapolis, IN USA
[9] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4146
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
    Zhu, A.
    Finn, R.
    Galle, P.
    Llovet, J.
    Blanc, J. F.
    Okusaka, T.
    Chau, I.
    Abada, P.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Outcomes By Baseline Alpha-Fetoprotein (AFP) Levels in the Phase 3 Celestial Trial of Cabozantinib (C) Versus Placebo (P) in Previously Treated Advanced Hepatocellular Carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony B.
    Meyer, Timothy
    Rimassa, Lorenza
    Merle, Philippe
    Chan, Stephen L.
    Tran, Albert
    Parnis, Francis
    Tam, Vincent C.
    Cattan, Stephane
    Markby, David W.
    Clary, Douglas O.
    Cheng, Ann-Lii
    Kelley, Robin Kate
    HEPATOLOGY, 2018, 68 : 533A - 534A
  • [33] Ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein following non-sorafenib-based therapy: interim results from phase 3 REACH-2 expansion cohort
    Finn, R.
    De Toni, E.
    Yau, T. C. C.
    Yen, C. -J.
    Hsu, C. -H.
    Chan, S.
    He, A. R.
    Galle, P.
    Trojan, J.
    Stirnimann, G.
    Baron, A.
    Acosta-Rivera, M.
    Goyal, L.
    Wang, C.
    Abada, P.
    Widau, R.
    Zhu, A.
    SWISS MEDICAL WEEKLY, 2020, : 27S - 27S
  • [34] PATIENT-REPORTED OUTCOMES (PROS) WITH RAMUCIRUMAB VERSUS PLACEBO IN CHINESE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AND ELEVATED ALPHA-FETOPROTEIN FROM THE RANDOMIZED PHASE 3 REACH-2 STUDY
    Chen, X.
    Shao, G.
    Bai, Y.
    Gu, S.
    Gu, K.
    Zhang, Q.
    Zhang, W.
    Liu, J.
    Zhou, L.
    Qin, S.
    VALUE IN HEALTH, 2022, 25 (12) : S19 - S20
  • [35] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study
    De Toni, E. N.
    Finn, R. C.
    Yau, Chung Cheung T.
    Yen, C. -J.
    Hsu, C. -H.
    Chan, S. L.
    He, A. R.
    Galle, P.
    Trojan, J.
    Stirnimann, G.
    Baron, A.
    Acosta-Rivera, M.
    Goyal, L.
    Wang, C.
    Abada, P.
    Widau, R.
    Zhu, A. X.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 125 - 126
  • [36] Serum alpha-fetoprotein (AFP) levels in patients with advanced hepatitis C-associated liver disease without hepatocellular carcinoma: Results from the HALT-C trial.
    Di Bisceglie, AM
    Dienstag, J
    Bonkovsky, H
    Sterling, R
    Chung, R
    Everhart, J
    Wright, E
    HEPATOLOGY, 2003, 38 (04) : 434A - 434A
  • [37] Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)
    Meyer, T.
    Finn, R.
    Kudo, M.
    Kang, Y.
    Yen, C.
    Galle, P.
    Llovet, J.
    Assenat, E.
    Brandi, G.
    Motomura, K.
    Okusaka, T.
    Hubner, R.
    Karwal, M.
    Baron, A.
    Ikeda, M.
    Liang, K.
    Wang, C.
    Widau, R.
    Schelman, W.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y.
    Cicin, I.
    Harris, W. P.
    Banu, E.
    Sarker, D.
    Tan, B.
    van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis
    Waldschmidt, D.
    Teufel, M.
    Koechert, K.
    Meinhardt, G.
    Bruix, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 281 - 282
  • [40] Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2)
    Reig, Maria
    Galle, Peter R.
    Kudo, Masatoshi
    Finn, Richard S.
    Llovet, Josep M.
    Schelman, William R.
    Liang, Kun
    Wang, Chunxiao
    Widau, Ryan C.
    Abada, Paolo
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345